Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Antibody; HIV-2

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86702 refers to the laboratory test for the detection of antibodies specific to HIV-2, which is one of the two types of the Human Immunodeficiency Virus (HIV). HIV-2 is primarily found in West Africa and is less common than HIV-1, but it can still lead to Acquired Immunodeficiency Syndrome (AIDS) if left untreated. The transmission of HIV-2 occurs through similar routes as HIV-1, including sexual contact, exposure to unscreened blood, sharing of needles, and from mother to child during pregnancy or breastfeeding. The immune system is significantly affected by HIV as the virus targets and destroys CD4 T cells, which are crucial for maintaining the body's immune response. The presence of antibodies to HIV-2 indicates that the body has been exposed to the virus and is mounting an immune response. The test performed under this code is qualitative, meaning it determines whether antibodies to HIV-2 are present or absent in the blood sample. This test is essential for diagnosing HIV-2 infections and guiding further clinical management. For comprehensive testing, it is important to note that CPT® Code 86701 is used for HIV-1 antibody screening, while CPT® Code 86703 is applicable for tests that screen for both HIV-1 and HIV-2 antibodies simultaneously.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 86702 is indicated for the testing of individuals who may have been exposed to HIV-2. The following conditions or situations warrant the use of this test:

  • High-Risk Sexual Behavior Individuals engaging in unprotected sexual intercourse with partners of unknown HIV status or known HIV-positive status.
  • Intravenous Drug Use Individuals who share needles or other drug paraphernalia, increasing the risk of HIV transmission.
  • Mother-to-Child Transmission Pregnant women who may transmit the virus to their child during pregnancy or breastfeeding.
  • Symptoms of HIV Infection Patients presenting with symptoms consistent with acute HIV infection, such as fever, fatigue, and swollen lymph nodes.
  • Routine Screening Individuals undergoing routine screening for sexually transmitted infections (STIs) or as part of a comprehensive health assessment.

2. Procedure

The procedure for testing antibodies to HIV-2 using CPT® Code 86702 involves several key steps:

  • Sample Collection A blood sample is obtained from the patient, typically through venipuncture. This sample is collected in a sterile container to prevent contamination and ensure accurate test results.
  • Laboratory Processing The collected blood sample is sent to a laboratory where it undergoes processing. The laboratory will isolate the serum from the blood cells, which is necessary for the subsequent testing.
  • Qualitative Testing The laboratory performs a qualitative enzyme immunoassay (EIA) to detect the presence of antibodies specific to HIV-2. This test involves adding specific antigens to the serum sample, which will bind to any HIV-2 antibodies present.
  • Result Interpretation After the testing process, the laboratory interprets the results. A positive result indicates the presence of antibodies to HIV-2, suggesting exposure to the virus, while a negative result indicates no detectable antibodies.
  • Reporting The results are documented and reported to the healthcare provider, who will discuss the findings with the patient and determine any necessary follow-up actions or treatments.

3. Post-Procedure

After the procedure, patients may be advised on the following post-procedure care and considerations:

Patients should be informed about the importance of follow-up testing, especially if the initial test result is positive, as confirmatory testing may be required to establish a definitive diagnosis. Additionally, individuals who test positive for HIV-2 should receive counseling regarding treatment options, lifestyle modifications, and preventive measures to reduce the risk of transmission to others. It is also essential for healthcare providers to discuss the implications of a positive result, including the need for regular monitoring and potential antiretroviral therapy. Patients should be encouraged to maintain open communication with their healthcare provider regarding any symptoms or concerns that may arise following the test.

Short Descr HIV-2 ANTIBODY
Medium Descr ANTIBODY HIV-2
Long Descr Antibody; HIV-2
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 235 - Other Laboratory
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
92 Alternative laboratory platform testing: when laboratory testing is being performed using a kit or transportable instrument that wholly or in part consists of a single use, disposable analytical chamber, the service may be identified by adding modifier 92 to the usual laboratory procedure code (hiv testing 86701-86703, and 87389). the test does not require permanent dedicated space, hence by its design may be hand carried or transported to the vicinity of the patient for immediate testing at that site, although location of the testing is not in itself determinative of the use of this modifier.
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
GA Waiver of liability statement issued as required by payer policy, individual case
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GW Service not related to the hospice patient's terminal condition
GZ Item or service expected to be denied as not reasonable and necessary
SA Nurse practitioner rendering service in collaboration with a physician
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2013-01-01 Changed Short Descriptor changed.
1993-01-01 Added First appearance in code book in 1993.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"